Naturecell
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Naturecell is listed on KOSDAQ and classified under Health Care, Pharmaceuticals. Its market value is US$1.1B. In FY2025 it reported revenue of US$15.6M and an operating loss of US$2.8M.
A written company profile is not available yet; the facts above come from exchange and DART data.
Naturecell in five facts
Where is Naturecell listed and in which sector?
Naturecell (Korean name: 네이처셀) trades under KRX code 007390 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Naturecell?
Its market capitalisation was US$1.1B on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Naturecell's latest annual revenue and operating profit?
For fiscal year 2025, Naturecell reported revenue of US$15.6M, an operating loss of US$2.8M and a net loss of US$2.1M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was down 35.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Material event reportOct 15
- Decision to acquire shares/equity in another company
Naturecell disclosed an acquisition of Nature Cell America Inc., worth US$6.99M.
M&A · Aug 26 - Rights offering (paid-in capital increase) decision (subsidiary)
Naturecell's wholly owned U.S. subsidiary, Nature Cell America Inc., decided a shareholder-allotment rights offering of 700,000 common shares at US$9.98 per share to raise US$6.99M of facility funds for expanding its Maryland research facility, with payment due September 8, 2026.
Capital raise · Aug 26 - Material event report (convertible bonds)
Naturecell disclosed convertible bonds to raise US$11.5M, about 1.1% of its market value.
Capital raise · Jul 22 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Jan 26